

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

#### **(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND (2) CONTINUED SUSPENSION OF TRADING**

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024 and 30 September 2024 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a) of the Rules (the “**Listing Rules**”) governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

#### **UPDATE ON PROGRESS OF RESUMPTION**

As disclosed in the announcement of the Company on 28 June 2024, the Stock Exchange has set out the Resumption Guidance for the Company as follows:

- (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (ii) demonstrate the Company’s compliance with Rule 13.24; and
- (iii) inform the market of all material information for the Shareholders and potential investors to appraise the Company’s position.

The Company must meet all resumption guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has primary responsibility to devise its action plan for resumption. The Stock Exchange may modify or supplement the Resumption Guidance if the Company’s situation changes.

Under Rule 6.01A of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 1 October 2025. If the Company fails to remedy the issues causing its trading suspension, fulfill the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by 1 October 2025, the Listing Division of the Stock Exchange will recommend the Listing Committee of the Stock Exchange to proceed with the cancellation of the Company's listing. Under Listing Rules 6.01 and 6.10, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate.

## **QUARTERLY UPDATE ON RESUMPTION PROGRESS**

### **Publication of Outstanding Financial Results**

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2023 Annual Results no later than three months after the end of the financial year (i.e. on or before 31 March 2024). Delay in publishing the 2023 Annual Results constitutes non-compliance with Rule 13.49(1) of the Listing Rules.

Pursuant to Rule 13.48(1) of the Listing Rules, the Company is required to publish an interim report, or a summary interim report not later than three months after the end of that period of six months ended 30 June 2024 (i.e. on or before 30 September 2024) (the "**2024 Interim Results**"). Delay in publishing the 2024 Interim Results constitutes non-compliance with Rule 13.48(1) of the Listing Rules.

As disclosed in the announcement of the Company dated 30 September 2024, the expected date of the publication of the 2023 Annual Results will be postponed until the end of November 2024.

Accordingly, the expected date of the publication of the 2024 Interim Results will be postponed until the end of December 2024.

### **Business Operation**

The Company is principally engaged in (i) footwear; (ii) financial services; (iii) healthcare; and (iv) online medical services business. Based on the information available to the Board, the Company's footwear business generates most of the Company's revenue, while the Group's business on financial services, healthcare and online medical services is operating at a minimal level.

The Board will continue to assess and monitor the impact of the suspension of trading (if any) on the operations and financial performance of the Company, including publication of announcement(s) in relation to the business operations of the Group, as and when appropriate.

The Board is also taking appropriate steps to fulfill the other conditions in the Resumption Guidance and will update the Shareholders and potential investors of the Company on, among others, the progress as and when appropriate.

### **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024, and will remain suspended pending the release of an announcement for the 2023 Annual Results and the 2024 Interim Results. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

**The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.**

By Order of the Board  
**TATA Health International Holdings Limited**

Hong Kong, 4 October 2024

*As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.*